Insmed Incorporated(INSM)
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Latest News & Analysis
Insmed (INSM): Brensocatib FDA Update, ARIKAYCE Sales, and Market Outlook
Analysis of Insmed (INSM): FDA update on Brensocatib, ARIKAYCE sales, international strategies, and Q4 2024 financials. Actionable insights for investors.
Insmed (INSM): Brensocatib's FDA Decision Looms - A Comprehensive Analysis
Insmed awaits FDA decision on brensocatib (August 12, 2025). No advisory committee suggests streamlined approval. Q4 loss wider, but ARIKAYCE strong. Key insights inside.
Insmed (INSM): Brensocatib FDA Review, ARIKAYCE Growth, and Financial Outlook
Insmed's brensocatib nears potential FDA approval amid strong ARIKAYCE sales. Q4 losses spark caution, but analysts see potential. A deep dive into INSM's outlook.
Insmed (INSM): Brensocatib's FDA Journey, ARIKAYCE's Ascent, and Future Prospects
Insmed (INSM) awaits a pivotal FDA decision on brensocatib for bronchiectasis. Strong ARIKAYCE growth contrasts with wider losses, shaping its future prospects.
Insmed (INSM): Brensocatib's FDA Path, ARIKAYCE Growth, and ATS 2025 Insights
Analysis of Insmed's brensocatib FDA review, ARIKAYCE sales, and ATS 2025 insights. Strategic focus, market performance, and healthcare policy impacts explored.
Insmed (INSM) Capital Raise and PAH Trial Success: A Deep Dive
Insmed's recent $750M capital raise and positive PAH trial results signal strong growth potential, redefining its biopharmaceutical market position.
Insmed (INSM) Analysis: Pipeline Success & Strategic Capital Raise
Insmed's stock surged on clinical trial success and a strategic capital raise, signaling a transformative period for the biopharmaceutical firm.
Insmed Stock Jumps on Strong PAH Trial Results, Capital Raise
Insmed's stock surged following positive PAH trial results, exceeding expectations. A $650M offering aims to fund pipeline growth amid shifting market dynamics.
Insmed Incorporated (INSM) Phase 2b Success, Capital Raise, and Q2 Earnings Preview
Insmed (INSM) delivers strong Phase 2b results for TPIP in PAH, secures $750M capital raise, and prepares for Q2 earnings amid competitive biotech landscape.
Insmed Incorporated Market Analysis: Brensocatib FDA Review, ARIKAYCE Growth, and Strategic Pipeline Progress
Insmed’s August 2025 FDA decision on Brensocatib, robust ARIKAYCE sales, and strategic pipeline advances highlight key growth and valuation inflection points.
Insmed Incorporated: Brinsupri Approval and Commercial Revenue Impact
Insmed (INSM) stock rallied after FDA approval of Brinsupri; analysis examines revenue, balance sheet, analyst revisions and the commercial runway for launch.
Insmed (INSM): Brinsupri Launch, Revenue Growth and Balance-Sheet Risks
FDA approval and $88,000 WAC for Brinsupri reshapes revenue potential; 2024 revenue +19.17% to $363.71M but net loss widened to -$913.77M and leverage metrics conflict.
Insmed (INSM): Brinsupri Approval, Cash Runway and Revenue Upside
FDA approval for Brinsupri turns Insmed into a multi-product respiratory player. Key metrics: **$130.49** share price, **$27.58B** market cap, ARIKAYCE guide **$405–425M**.